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Abstract: (1) Background: Nowadays, the use of microsurgical free flaps is a standard operative
procedure in reconstructive surgery. Still, thrombosis of the microanastomosis is one of the most
fatal postoperative complications. Clinical evaluation, different technical devices and laboratory
markers are used to monitor critical flap perfusion. Macrophage migration inhibitory factor (MIF),
a structurally unique cytokine with chemokine-like characteristics, could play a role in predicting
vascular problems and the failure of flap perfusion. (2) Methods: In this prospective observational
study, 26 subjects that underwent microsurgical reconstruction were observed. Besides clinical
data, the number of blood leukocytes, CRP and MIF were monitored. (3) Results: Blood levels of
MIF, C-reactive protein (CRP) and leukocytes increased directly after surgery. Subjects that needed
surgical revision due to thrombosis of the microanastomosis showed significantly higher blood levels
of MIF than subjects without revision. (4) Conclusion: We conclude that MIF is a potential and
innovative indicator for thrombosis of the microanastomosis after free flap surgery. Since it is easy to
obtain diagnostically, MIF could be an additional tool to monitor flap perfusion besides clinical and
technical assessments.
Keywords: macrophage migration inhibitory factor (MIF); free flap surgery; innovative surgical
methods; microanastomosis; ischemia
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1. Introduction
Reconstruction using free microsurgical flaps is a standard operative procedure to
close and reconstruct various skin and soft tissue defects. Still, thrombosis of the mi-
croanastomosis is one of the most fatal postoperative complications, requiring immediate
operative revision for flap salvage. Although different technical devices are used to moni-
tor postoperative flap perfusion, clinical evaluation of the flap seems to remains the gold
standard [1]. However, circulating blood biomarkers might be a promising additional tool
for this purpose, since they are rapidly released upon stimulus and easy to obtain.
The protein mediator macrophage migration inhibitory factor (MIF) might be a novel
tool in this context. MIF is a structurally unique pleiotropic cytokine, involved in acute
and chronic inflammatory processes and cancer [2–4]. Over the last few decades, it has
become clear that MIF functions as a chemokine-like cytokine, which promotes the directed
migration and recruitment of leukocytes to inflammatory sites [5,6]. MIF interacts with
surface CD74, but the leukocyte recruitment is mediated by a non-cognate binding to
the chemokine receptors CXCR2 and CXCR4 [5], leading to vascular diseases such as
atherosclerosis [6,7]. Furthermore, MIF has been demonstrated to be involved in endothelial
progenitor cell mobilisation after free flap surgery [8] and seems to be involved in flap
vascularization in a murine model [9]. In addition, MIF has proven to serve as a promising
potential biomarker in different diseases throughout different clinical fields [10,11]. Due
to its affinity to the vascular system, MIF may play a role for indicating flap ischemia
and thrombosis.
In this study, we focus on MIF as a potential and beneficial tool to evaluate and
predict critical flap perfusion. Higher MIF values were found in the postoperative course
of subjects needing surgical revision, which confirmed the potential of MIF as biomarker in
free flap surgery.
2. Materials and Methods
2.1. Subjects
This prospective observational study included 26 subjects who underwent free flap
surgery at the Department of Plastic Surgery and Hand Surgery, Burn Center of the RWTH
Aachen University (Table 1). Ten of the subjects were female. The mean age of all subjects
was 47.8 years, ranging from 19 to 71. Five subjects needed a surgical flap revision of the
microanastomosis. Two flaps were lost due to necrosis. In one case, microsurgical problems
already occurred during the initial operation.
Exclusion criteria were: age <18 years, multiple flap surgeries, any form of hematolog-
ical disease, smoking and acute illness or infection.
None of the patients had taken non-steroidal anti-inflammatory drugs, oral anticoag-
ulation or platelet aggregation inhibitors. Patients received anti-thrombosis prophylaxes
using 5000 UI of low-molecular-weight heparin subcutaneously on a daily basis.
Blood samples were collected after written informed consent of the concerning patients
and with the approval of the local ethics committee.
2.2. Methods
Blood samples were taken by venous puncture 24 h prior to the operation and 3, 6, 12,
24, 36, 48, 72, 96 and 120 h after the operation for MIF determination. Leukocyte and C-
reactive protein (CRP) levels, being very easy to obtain, were monitored following a clinical
standard procedure 24 h prior to the operation and 24, 48 and 120 h after the operation.
Blood samples (collected in citrate tubes) were spun at 3500× g for 10 min. Plasma
was stored at −80 ◦C until analysis. MIF concentrations were determined as published
previously [12,13]. Leukocyte and CRP levels were routinely determined by the clinical
chemistry laboratory of the University Hospital of the RWTH Aachen, Germany. Blood
analyses were not performed blinded.
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Patient 1 66 M elbow antero lateral thigh flap n n
Patient 2 41 M hand antero lateral thigh flap n n
Patient 3 53 M abdomen latissimus dorsi flap n n
Patient 4 42 F lower leg radial forearm flap n n
Patient 5 55 M foot latissimus dorsi flap n n
Patient 6 19 M hand parascapular n n
Patient 7 50 M lower leg latissimus dorsi flap n n
Patient 8 25 M face gracilis flap n n
Patient 9 27 M lower leg latissimus dorsi flap n n
Patient 10 50 M lower leg antero lateral thigh flap n n
Patient 11 53 M lower leg gracilis flap n n
Patient 12 46 F breast diep flap n n
Patient 13 71 F lower leg radial forearm flap n n
Patient 14 59 M lower leg antero lateral thigh flap y n
Patient 15 66 M lower leg gracilis flap y n
Patient 16 63 F breast diep flap n n
Patient 17 71 F lower leg gracilis flap n n
Patient 18 51 F breast diep flap n n
Patient 19 59 M foot antero lateral thigh flap n n
Patient 20 48 F breast diep flap n n
Patient 21 29 M knee gracilis flap y y
Patient 22 52 F breast diep flap n n
Patient 23 26 M axilla antero lateral thigh flap n n
Patient 24 30 M lower leg antero lateral thigh flap y y
Patient 25 42 F breast diep flap y n
Patient 26 51 F breast diep flap n n
Age
Mean 47.885




Data are presented in mean ± standard deviation (SD). For statistical analysis, sig-
nificance was evaluated using a 1-way-analysis of variance (ANOVA) in the case of more
than two groups and the Student’s t-test (two groups); p-values < 0.05 were consid-
ered significant.
3. Results
In this study, we investigated whether MIF is a potential indicator for postoperative
flap ischemia after free flap surgery.
The perioperative levels of MIF are shown in Figure 1. Six hours after surgery, MIF
levels show a significant increase (p < 0.05), that peak at 24 h postoperatively (p < 0.05). This
is followed by a significant decrease in MIF levels after 48 h (p < 0.05) and 120 h (p < 0.05)
after surgery. The location of the defect or flap did not have a significant effect on the MIF
levels (data not shown).
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Figure 1. Postoperative MIF levels. Columns indicate mean values; error bars refer to the correspond-
ing standard deviations (* p ≤ 0.05).
Figure 2 demonstrates the level of leukocytes pre- and postoperatively. A slight but
significant (p < 0.05) increase in leukocytes can be observed 24 h after surgery, followed by
a delayed but significant decrease (p < 0.05) at 120 h after the free flap surgery. After 120 h,
levels of leukocytes almost fall back to baseline values (7.9 vs. 8.1 LEU [109*l−1]; p = 0.61).
≤
≤
Figure 2. Postoperative levels of leukocytes. Columns indicate mean values; error bars refer to the
corresponding standard deviations (* p ≤ 0.05).
The levels of CRP are shown in Figure 3. As MIF and leukocyte levels, CRP levels
show a significant increase (p < 0.05) 24 h after surgery. Further postoperative monitoring
showed no significant change of CRP levels.
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Figure 3. Postoperative CRP levels. Columns indicate mean values; error bars refer to the corre-
sponding standard deviations (* p ≤ 0.05; n.s. = not significant).
To determine the role of MIF during and after necessary surgical revision, we divided
the group into subjects that needed surgical revision due to thrombosis of the microanas-
tomosis and subjects without surgical revision. With respect to MIF levels, the data are
shown in Figure 4.
≤
≤
Figure 4. Postoperative MIF levels divided into two groups. Subjects that needed surgical revision
due to thrombosis of the microanastomosis (grey) and subjects without surgical revision (black).
Error bars refer to the corresponding standard deviations (* p ≤ 0.05).
The group needing revision surgery demonstrated significantly higher MIF values
during the postoperative course, as demonstrated at 72 (p < 0.05), 96 (p < 0.05) and 120
(p < 0.05) hours after the initial free flap surgery compared to the subjects without surgical
revision. This also applied to CRP levels 120 h after surgery (p < 0.05). In addition, no
significant difference of MIF levels could be detected between an arterial or venous throm-
bosis of the microanastomosis (data not shown). MIF levels of all subjects are additionally
presented in Figure S1. The remaining CRP levels and all Leukocyte levels in contrast did
not show any significant difference between those two groups (Figures 5 and 6).
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≤
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Figure 5. Postoperative CRP levels divided into two groups. Subjects that needed surgical revision
due to thrombosis of the microanastomosis (grey) and subjects without surgical revision (black).
Error bars refer to the corresponding standard deviations (* p ≤ 0.05).
≤
α
Figure 6. Postoperative levels of leukocytes divided into two groups. Subjects that needed surgical
revision due to thrombosis of the microanastomosis (grey) and subjects without surgical revision
(black). Error bars refer to the corresponding standard deviations (* p ≤ 0.05).
4. Discussion
This study for the first time addressed the potential use of the cytokine MIF as a
potential marker for flap ischemia following free flap surgery.
Free flap surgery is a routinely used method to cover various defects. If a prob-
lem of the microanastomosis occurs, immediate surgical intervention is essential for flap
salvage [14]. Different techniques have been described to monitor postoperative flap perfu-
sion such as the handheld Doppler ultrasound probe, laser Doppler flowmetry, nuclear
medicine, near-infrared spectrometry, perfusion photoplethysmography, surface temper-
ature measurement, confocal microscopy, white light spectroscopy, subcutaneous pH
measurement, multispectral spatial frequency domain imaging, orthogonal polarized light,
sidestream dark field imaging, CO2 monitoring, pulse oximetry, fluorometry, injectable
biosensors and Cook–Swartz Doppler [14–28]. However, clinical evaluation of the flap
seems to remain the gold standard [1].
In addition to technical devices, the use of biomarkers is of increasing interest as they
may further increase the sensitivity and specificity in the clinical decision-making process.
Koerdt et al. monitored serum levels of procalcitonin in head and neck free flaps [29]. A
higher plasma level of IL-8 and TNF-α after venous thrombosis in a canine model were
observed by Du et al. [30]. Hill et al. described low hemoglobin and hematocrit levels as
preoperative risk markers before free flap surgery [31]. Another clinical study by Kloeters
et al. showed that higher levels of prothrombin fragment and thrombin–antithrombin
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III complex due to delayed microsurgical reconstruction present a higher risk of flap
failure [32].
Generally, in this study, an increase in MIF levels can be observed 24 h after the
operation of free flaps. This also applies to the levels of leukocytes and CRP, indicating a
more general inflammation due to the extended operation. However, this is well in line
with observations our group observed before [8].
Furthermore, MIF already has been described to be released after hypoxia or ischemia
and to be involved in ischemia/reperfusion injury [33].
However, when comparing the group of subjects in this study needing surgical re-
vision with the group of subjects without revision of the microanastomosis, higher MIF
values were detected 72, 96 and 120 h after the primary operation for the group that needed
revision. Thus, MIF could be interpreted as a potential indicator for the need of surgical
revision, since all surgical revised subjects demonstrated problems of the microanastomosis.
In addition, this effect was also seen with respect to CRP levels after 120 h. However, the
conclusion of this effect is limited for CRP due to the limited time points in this study.
This is in line with the observation of Wright et al. who interpreted a CRP peak four days
after flap surgery as an indicator for infection and need for further surgery [34]. However,
CRP represents a rather general marker for inflammation. Since MIF seems to act very
specifically after ischemia/reperfusion [33], its role as a biomarker in this context could
be very prominent. Nevertheless, in all surgically revised cases, the clinical decision for
revision was made before a second rise of MIF-levels could be observed. In this experi-
mental setting with only a moderate number of subjects, blood samples were stored until
analysis with an ELISA to determine the amount of MIF. For a “true” clinical setting with
potential decisions concerning revision surgery, this test procedure would be too slow. A
quick “MIF” bedside test could be the potential solution for this time problem. However,
the development of such a test is connected with high costs and would only be of interest
if the sensitivity and specificity of the test are high enough. Thus, the role of the cytokine
MIF as a biomarker in free flap surgery needs to be elucidated further.
5. Conclusions
We conclude that the cytokine MIF is a potential and innovative marker for flap
ischemia due to thrombosis of the microanastomosis and thus, a potential indicator for
necessary surgical revision after free flap surgery. Since MIF-levels are easy to obtain,
we are convinced that it could play a role as an additional tool to monitor flap perfusion
besides clinical and technical assessments. However, besides faster high quality test
procedures, more clinical studies with larger cohorts are needed to underpin the role of
MIF in this context.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/healthcare9060616/s1, Figure S1: MIF-levels of all subjects. Levels of subjects needing surgical
revision are connected with lines.
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